Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

Conditions: Metastatic Colorectal Cancer Interventions: Drug: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials